CTC Counts May Help Predict mCRPC Patient Survival

Share this article:

Circulating tumor cell (CTC) enumeration (CELLSEARCH), along with measuring lactate dehydrogenase (LDH) as part of a composite biomarker panel, may be a good surrogate for survival in patients with metastatic castration-resistant prostate cancer (mCRPC).

John Schieszer has the latest on the story in today in today's Medical Minute.

Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in The Medical Minute

New Link Between Exercise, PCa Found in Blood Vessels

Researchers found that PCa patients who walked at a faster pace were more likely to have healthier blood vessels.

Melatonin Levels Affect Prostate Cancer Risk

Researchers conducted a study in Iceland that found an association between prostate cancer risk and quality of sleep.

Geographic Differences for Children on Donor Waitlist

A new study is suggesting there is substantial geographic variation in deceased donor kidney waiting times.